{"entity":{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","aka":[],"tldr":"Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.","summary":"Cusatuzumab (OV-1001, JNJ-74494550, ARGX-110) is a monoclonal antibody developed by OncoVerity. Its target is CD70. ClinicalTrials.gov describes the intervention as: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in acute myeloid leukaemia. The largest, NCT06384261, plans to enrol 140 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Cusatuzumab","url":"https://clinicaltrials.gov/search?intr=OV-1001"},{"label":"Sponsor page","url":"https://www.oncoverity.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["cd70"],"drugs":[],"companies":["oncoverity"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04023526"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"OV-1001, JNJ-74494550, ARGX-110","modality":"monoclonal antibody","mechanism":"Monoclonal antibody directed at CD70, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cusatuzumab/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/"}],"company":[{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/"},{"id":"oncoverity","kind":"company","name":"OncoVerity","route":"/companies/oncoverity/"}],"trial":[{"id":"nct04023526","kind":"trial","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","route":"/trials/nct04023526/"}]}}